Date Action Amount Person Type
Feb 07, 2024 Buy 214 500 Metzger Michael A Stock Options (Right to buy)
Feb 07, 2024 Buy 39 000 Metzger Michael A Common Stock
Feb 07, 2024 Buy 107 250 Metzger Michael A Common Stock
Feb 07, 2024 Buy 70 000 Goldan Keith A. Stock Options (Right to buy)
Feb 07, 2024 Buy 11 700 Goldan Keith A. Common Stock
Feb 07, 2024 Buy 35 000 Goldan Keith A. Common Stock
Feb 07, 2024 Buy 69 375 Gallagher Neil Stock Options (Right to buy)
Feb 07, 2024 Buy 13 125 Gallagher Neil Common Stock
Feb 07, 2024 Buy 34 688 Gallagher Neil Common Stock
Feb 07, 2024 Buy 17 000 Huber Martin H. Jr. Common Stock
Feb 07, 2024 Buy 17 000 Jarrett Jennifer Common Stock
Feb 07, 2024 Buy 17 000 Katkin Keith Common Stock
Feb 07, 2024 Buy 17 000 Meury William Common Stock
Feb 07, 2024 Buy 17 000 Morrison Briggs Common Stock
Feb 07, 2024 Buy 34 000 Podlesak Dennis Common Stock
Feb 07, 2024 Buy 17 000 Legault Pierre Common Stock
Jan 31, 2024 Buy 1 183 Goldan Keith A. Common Stock
Aug 09, 2023 Buy 52 855 Morrison Briggs Common Stock
Aug 09, 2023 Sell 52 855 Morrison Briggs Common Stock
Aug 09, 2023 Sell 52 855 Morrison Briggs Stock Options (Right to buy)
Aug 02, 2023 Buy 35 000 Meury William Common Stock
Aug 02, 2023 Buy 24 000 Meury William Common Stock
Aug 02, 2023 Buy 24 000 Meury William Common Stock
Aug 02, 2023 Sell 24 000 Meury William Common Stock
Aug 02, 2023 Sell 35 000 Meury William Common Stock
Aug 02, 2023 Sell 24 000 Meury William Common Stock
Aug 02, 2023 Sell 24 000 Meury William Stock Options (Right to buy)
Aug 02, 2023 Sell 24 000 Meury William Stock Options (Right to buy)
Aug 02, 2023 Sell 35 000 Meury William Stock Options (Right to buy)
Jul 31, 2023 Buy 862 Goldan Keith A. Common Stock
Jul 10, 2023 Buy 52 855 Morrison Briggs Common Stock
Jul 10, 2023 Sell 52 855 Morrison Briggs Common Stock
Jul 10, 2023 Sell 52 855 Morrison Briggs Stock Options (Right to buy)
Jun 13, 2023 Sell 577 Goldan Keith A. Common Stock
Jun 09, 2023 Buy 28 273 Morrison Briggs Common Stock
Jun 09, 2023 Sell 24 582 Morrison Briggs Common Stock
Jun 09, 2023 Buy 24 582 Morrison Briggs Common Stock
Jun 09, 2023 Sell 28 273 Morrison Briggs Common Stock
Jun 09, 2023 Sell 28 273 Morrison Briggs Stock Options (Right to buy)
Jun 09, 2023 Sell 24 582 Morrison Briggs Stock Options (Right to buy)
May 09, 2023 Buy 52 855 Morrison Briggs Common Stock
May 09, 2023 Sell 52 855 Morrison Briggs Common Stock
May 09, 2023 Sell 52 855 Morrison Briggs Stock Options (Right to buy)
Apr 10, 2023 Buy 52 855 Morrison Briggs Common Stock
Apr 10, 2023 Sell 52 855 Morrison Briggs Common Stock
Apr 10, 2023 Sell 52 855 Morrison Briggs Stock Options (Right to buy)
Apr 10, 2023 Buy 250 000 Gallagher Neil Stock Options (Right to buy)
Apr 10, 2023 Buy 0 Gallagher Neil
Mar 13, 2023 Buy 52 854 Morrison Briggs Common Stock
Mar 13, 2023 Sell 52 854 Morrison Briggs Common Stock
Mar 13, 2023 Sell 52 854 Morrison Briggs Stock Option (Right to Buy)
Feb 15, 2023 Buy 17 428 Ordentlich Peter Common Stock
Feb 15, 2023 Buy 7 572 Ordentlich Peter Common Stock
Feb 15, 2023 Sell 17 428 Ordentlich Peter Common Stock
Feb 15, 2023 Sell 17 428 Ordentlich Peter Stock Options (Right to buy)
Feb 15, 2023 Sell 7 572 Ordentlich Peter Stock Options (Right to buy)
Feb 06, 2023 Buy 5 959 Metzger Michael A Common Stock
Feb 06, 2023 Sell 5 959 Metzger Michael A Common Stock
Feb 06, 2023 Sell 5 959 Metzger Michael A Stock Options (Right to buy)
Feb 06, 2023 Buy 52 854 Morrison Briggs Common Stock
Feb 06, 2023 Sell 52 854 Morrison Briggs Common Stock
Feb 06, 2023 Sell 52 854 Morrison Briggs Stock Options (Right to buy)
Feb 02, 2023 Buy 410 000 Metzger Michael A Stock Options (Right to buy)
Feb 02, 2023 Buy 32 000 Morrison Briggs Stock Options (Right to buy)
Feb 02, 2023 Buy 110 000 Madigan Catherine Stock Options (Right to buy)
Feb 02, 2023 Buy 110 000 Goldan Keith A. Stock Options (Right to buy)
Feb 02, 2023 Buy 90 000 Ordentlich Peter Stock Options (Right to buy)
Feb 02, 2023 Buy 17 000 Nolte Alexander Stock Options (Right to buy)
Feb 02, 2023 Buy 32 000 Podlesak Dennis Common Stock
Feb 02, 2023 Buy 16 000 Huber Martin H. Jr. Common Stock
Feb 02, 2023 Buy 16 000 Meury William Common Stock
Feb 02, 2023 Buy 16 000 Legault Pierre Common Stock
Feb 02, 2023 Buy 16 000 Katkin Keith Common Stock
Feb 02, 2023 Buy 16 000 Jarrett Jennifer Common Stock
Feb 01, 2023 Sell 69 Ordentlich Peter Common Stock
Jan 31, 2023 Buy 69 Ordentlich Peter Common Stock
Jan 13, 2023 Buy 10 000 Legault Pierre Common Stock
Jan 13, 2023 Buy 5 000 Legault Pierre Common Stock
Jan 13, 2023 Sell 5 000 Legault Pierre Common Stock
Jan 13, 2023 Sell 10 000 Legault Pierre Stock Options (Right to buy)
Jan 12, 2023 Buy 24 000 Legault Pierre Common Stock
Dec 05, 2022 Buy 220 000 Sabus Steve M Stock Options (Right to buy)
Dec 05, 2022 Buy 0 Sabus Steve M
Dec 05, 2022 Buy 0 Sabus Steve M
Dec 02, 2022 Buy 17 200 Ordentlich Peter Common Stock
Dec 02, 2022 Sell 17 200 Ordentlich Peter Common Stock
Dec 02, 2022 Sell 17 200 Ordentlich Peter Stock Options (Right to buy)
Dec 01, 2022 Buy 4 028 Ordentlich Peter Common Stock
Dec 01, 2022 Buy 3 772 Ordentlich Peter Common Stock
Oct 06, 2022 Buy 20 782 Katkin Keith Common Stock
Oct 06, 2022 Buy 9 117 Katkin Keith Common Stock
Oct 06, 2022 Sell 20 782 Katkin Keith Common Stock
Oct 06, 2022 Sell 20 782 Katkin Keith Stock Options (Right to buy)
Oct 06, 2022 Buy 16 231 Metzger Michael A Common Stock
Oct 06, 2022 Sell 16 231 Metzger Michael A Common Stock
Oct 06, 2022 Sell 16 231 Metzger Michael A Stock Options (Right to buy)
Oct 04, 2022 Buy 1 280 Metzger Michael A Common Stock
Oct 04, 2022 Sell 1 280 Metzger Michael A Common Stock
Oct 03, 2022 Buy 2 883 Metzger Michael A Common Stock
Sep 30, 2022 Buy 29 606 Metzger Michael A Common Stock
INSIDER POWER
40.920
Last 100 transactions
Buy: 2 711 593 | Sell: 1 085 664 (Shares)

Based on the 100 latest insides trades, we have calculated the insider power to be positive at a ratio of 40.920.

In total, the insiders bought 2 711 593 and sold 1 085 664 SNDX shares in the last 100 trades.

Click to get the best stock tips daily for free!

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that b... SNDX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT